PRAME protein expression in DICER1‐related tumours. (16th March 2022)

• Record Type: Journal Article
• Authors: Thorner, Paul S; Chong, Anne‐Sophie; Nadaf, Javad; Benlimame, Naciba; Marrano, Paula; Chami, Rose; Fu, Lili; Foulkes, William D
• Is Part Of: Journal of pathology. Volume 8:Number 3(2022)
• Page Start: 294
• Page End: 304
• Publication Date: 2022-03-16
• Subjects: DICER1 -- PRAME -- pleuropulmonary blastoma -- cystic nephroma -- anaplastic sarcoma of the kidney; Pathology -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.07
• DOI: 10.1002/cjp2.264
• Languages: English
• ISSNs: 2056-4538

Abstract

Abstract: DICER1 syndrome is an autosomal dominant tumour predisposition syndrome usually affecting persons under 30 years of age. Many of the associated benign and malignant lesions occur almost exclusively in DICER1 syndrome. One such tumour, pituitary blastoma (pitB), overexpresses PRAME 500x above control levels. PRAME (PReferentially expressed Antigen in MElanoma) is expressed in malignancies that are not DICER1‐related (e.g. melanoma). To address whether PRAME expression is part of the DICER1 phenotype, or simply a feature of pitB, a series of 75 DICER1 ‐mutated specimens and 33 non‐mutated specimens was surveyed using immunohistochemistry for PRAME, together with EZH2, which complexes with PRAME. In DICER1 ‐mutated specimens, positive staining for PRAME was only seen in malignant tumours; 7 of 11 histological types and 34/62 individual tumours were positive, while non‐tumourous lesions were always negative. Pleuropulmonary blastoma (PPB) showed a continuum in staining, with type I lesions being PRAME negative ( n = 7) but all type II and type III lesions PRAME positive ( n = 7). Similarly, cystic nephroma (CN) was negative ( n = 8), with anaplastic sarcoma of the kidney being positive ( n = 2). However, one atypical CN with mesenchymal cell proliferation was PRAME‐positive. Embryonal rhabdomyosarcoma (RMS) with DICER1 pathogenic variants (PVs) was positive for PRAME (5/6), but the same tumour type without DICER1 PVs was also positive (9/15). Staining for EZH2 corresponded to that seen with PRAME, validating the latter. This study leads us to conclude that (1) PRAME expression occurs in two‐thirds of DICER1‐related malignancies; (2) PRAME may be a marker for the progression that certain DICER1‐related lesions are thought to undergo, such as PPB and CN; and (3) PRAME expression in some tumours, such as RMS, appears to be an intrinsic feature of the tumour, rather than specifically related to DICER1 PVs. Therapy directed against PRAME may offer novel treatment options in patients with the DICER1 syndrome.